Results 91 to 100 of about 10,318 (317)

Association of GLP-1 receptor agonists with herpes risks in diabetes mellitus: a target trial emulation

open access: yesBMC Medicine
Background GLP-1 receptor agonists (GLP-1RA) are effective for glycemic control and cardiometabolic outcomes, but their infectious safety, particularly regarding herpes simplex virus (HSV) and herpes zoster (HZ), is underexplored.
Chi-Hsien Huang   +9 more
doaj   +1 more source

Combination GLP-1 and Insulin Treatment Fails to Alter Myocardial Fuel Selection Versus Insulin Alone in Type 2 Diabetes [PDF]

open access: yes, 2018
Context Glucagon-like peptide-1 (GLP-1) and the clinically available GLP-1 agonists have been shown to exert effects on the heart. It is unclear whether these effects occur at clinically used doses in vivo in humans, possibly contributing to CVD risk ...
Considine, Robert V.   +9 more
core   +1 more source

What Are the Impacts of GLP‐1 Drugs in Patients Needing Head/Neck Surgery?

open access: yes
The Laryngoscope, EarlyView.
Chelsea Gelboin‐Burkhart   +3 more
wiley   +1 more source

Sexual Safety Signals of Common Antidiabetic Drugs: Insights From FAERS Disproportionality Analysis

open access: yesAndrology, EarlyView.
ABSTRACT Background Erectile dysfunction is a prevalent and distressing complication of diabetes mellitus that markedly affects quality of life in male patients. Although the role of diabetes in erectile dysfunction is well‐established, potential drug‐induced sexual dysfunction associated with commonly prescribed antidiabetic medications remains ...
Shan Lin   +3 more
wiley   +1 more source

Levodopa Efficacy and GLP‐1 Receptor Agonists

open access: yes
Movement Disorders Clinical Practice, EarlyView.
Catherine Martinez   +3 more
wiley   +1 more source

Timing and duration of glucagon‐like peptide‐1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy

open access: yesActa Ophthalmologica, EarlyView.
Abstract Purpose To investigate the association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and nonarteritic anterior ischaemic optic neuropathy (NAION) in type 2 diabetes, examining treatment recency and cumulative duration. Methods This nationwide registry‐based nested case–control study utilizedz Danish health registries (1996 ...
Siar Niazi   +9 more
wiley   +1 more source

Patient-important outcomes in type 2 diabetes: The paradigm of the sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists

open access: yesDiabetes & Vascular Disease Research
The newfound knowledge in type 2 diabetes (T2D) during the past decade for the sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) is wealthy in favorable results for key patient-important outcomes ...
Kyriakos Kintzoglanakis   +3 more
doaj   +1 more source

Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP‐1 Receptor Agonist Therapy

open access: yesActa Paediatrica, EarlyView.
ABSTRACT Aim To explore changes in body composition in adolescents with obesity treated with glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) and their association with metabolic syndrome (MetS) components. Methods This real‐world retrospective study included adolescents (12–18 years) with obesity who received multidisciplinary lifestyle‐based ...
Adar Lopez   +11 more
wiley   +1 more source

Impact of Glucagon-Like Peptide-1 Receptor Agonists on Postoperative Outcomes Following Ankle Fracture Open Reduction and Internal Fixation

open access: yesFoot & Ankle Orthopaedics
Research Type: Level 3 - Retrospective cohort study, Case-control study, Meta-analysis of Level 3 studies Introduction/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are quickly growing in popularity as effective tools in the management of ...
Joshua Morningstar BS   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy